NY-FINSBURY-GLOVER
Following their announcement on 7 July 2020, Finsbury, The Glover Park Group (GPG) and Hering Schuppener have completed their merger and management buy-in of 49.99 per cent of the combined business. The merger will create a pre-eminent global strategic communications and public affairs consultancy, operating from 18 offices with almost 700 consultants. WPP will remain a 50.01 per cent investor and Mark Read, CEO of WPP, will join the Board.
Over the past six months, the three firms have worked to integrate their operations and today announce global executive leadership teams, who will be charged with overseeing operations and driving growth across their regions.
Alexander Geiser serves as Global CEO and Regional CEO for Europe, Mike Feldman and Winnie Lerner as Regional Co-CEOs for North America and Faeth Birch as Regional CEO for the United Kingdom, Middle East and Asia. As previously announced, Carter Eskew and Roland Rudd are Co-Chairmen of the firm.
The merger of the three firms comes at a time when companies and organizations are navigating through an increasingly complex operating environment and balancing challenging social, political and economic dynamics. Finsbury Glover Hering will be a trusted partner to its clients, supporting their efforts to manage through these cross-currents and achieve their business goals. The combined entity will offer clients new reach across stakeholder audiences and geographies, allowing for fully-integrated communications campaigns.
Roland Rudd, Co-Chairman, said, “This is a great moment for Finsbury Glover Hering, we are all energised and excited by the opportunity to create a very special, owner-led firm and be an even better partner to our existing and new clients. We thank them for their support.”
“I am proud to have such a talented team leading our people across the world. I have worked with both Mike and Winnie for decades and have collaborated with Alex and Faeth on global projects over the years. The future of our global firm could not be in better hands,” said Carter Eskew, Co-Chairman.
Alexander Geiser, CEO, added: “We have received overwhelmingly positive feedback from clients and employees alike for this step. Both externally and internally, many have already experienced us as one firm. Now it has really become one firm – with a global brand, balance sheet and governance.”
About Finsbury Glover Hering
Finsbury Glover Hering is a new pre-eminent global strategic communications advisory firm, headquartered in New York City with almost 700 multidisciplinary experts across the world’s major financial, government, business and cultural centers. The company was formed through the merger of the leading strategic communications consultancies Finsbury, The Glover Park Group (GPG) and Hering Schuppener. The firm provides combined support in Business Transformation, Corporate Reputation & Leadership Strategies, Crisis & Issues Management, Government Relations & Policy and Advocacy as well as Transaction & Financial Communications, supported by research & insights, digital strategy, design and creative solutions.
Finsbury Glover Hering serves its global client base from offices in Abu Dhabi, Beijing, Berlin, Brussels, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, London, Los Angeles, Munich, New York, Riyadh, Shanghai, Singapore, Tokyo and Washington D.C.
Find more information visit www.fgh.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005217/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 12:58:00 CET | Press release
Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release
ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin
BoConcept, Lego, Lurpak, and Pandora are among the Honoured Winners of the 2025-2026 World Branding Awards in Osaka17.11.2025 11:48:00 CET | Press release
The 20th World Branding Awards celebrated the success and achievements of leading brands across National, Regional, and Global categories. In the 2025–2026 edition, over 1,092 brands from 66 countries were nominated as “Brand of the Year”. From this distinguished selection, fewer than 100 brands emerged as winners, representing the highest standards of excellence across the three tiers of recognition. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. Over 80 international guests joined the celebration, hosted by Allie Sakakibara and enriched by a keynote from Miho Noguchi on immersive brand experiences. Honoured as Global winners in branding across diverse industries were Cadbury (USA), IKEA (Sweden), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). Winners from Denmark include BoConcept, Lego, Lurpak, and Pandora.Other National tier winners incl
Global Winners of the 2025–2026 World Branding Awards Announced at First-Ever Japan Ceremony17.11.2025 11:43:00 CET | Press release
Now in its 20th edition, the World Branding Awards continues to spotlight the world’s most impactful and trusted brands. This year, over 1,092 brands from 66 countries were nominated as “Brand of the Year”, with less than 100 declared Winners across Global, Regional, and National tiers. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. The 2025–2026 edition welcomed over 80 international guests and was presented by the acclaimed Allie Sakakibara. The evening was further elevated by a keynote presentation from Miho Noguchi, who shared insights on building emotional resonance through immersive brand experiences. Global Tier winners celebrated their outstanding branding excellence across various industries, including IKEA (Sweden), Lurpak (Denmark), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). These brands consistently demonstrated strength, inf
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 11:30:00 CET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom